Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days

The primary objective is to determine if there is a correlation between reductions in corneal staining and improvements in corneal barrier function.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must have moderate corneal staining and exhibit a need to use artificial tears.

Exclusion criteria

Patients can not participate in any other ophthalmic drug or device clinical trial within 30 days of the baseline visit.

Treatment and study plan

Systane® Ultra

Other

Systane® Ultra 1-2 drops, 4 times per day for 30 days

Primary outcomes

Percent change from baseline of corneal fluorescein

Time frame: 30 days

Secondary outcomes

Adverse event occurence

Time frame: 30 Days

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 2009
Primary completion: 2009
Study completion: 2009
First posted: Jul 27, 2009
Registry last updated: Nov 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed